Haploidentical stem cell transplantation with early ATG and low-dose cyclophosphamide
Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide
This study is testing if giving a special medication and a lower dose of chemotherapy right after a stem cell transplant can help patients who don't have a matched donor recover better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | cyclophosphamide |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06041893 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of early administration of anti-thymocyte globulin (ATG) and low-dose post-transplant cyclophosphamide in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HCT). The research is conducted at Samsung Medical Center and aims to define optimal strategies for haplo-HCT in patients who lack a matched donor. By focusing on a single center, the study seeks to provide detailed insights into the outcomes associated with this specific treatment approach.
Who should consider this trial
Good fit: Ideal candidates are patients undergoing haploidentical hematopoietic stem cell transplantation at Samsung Medical Center.
Not a fit: Patients who are unable to provide consent or do not meet the eligibility criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve transplant outcomes and reduce complications for patients undergoing haploidentical stem cell transplantation.
How similar studies have performed: While haploidentical stem cell transplantation is increasingly used, the specific combination of early ATG and low-dose cyclophosphamide is still being explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center. Exclusion Criteria: * A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.
Where this trial is running
Seoul
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Keon Hee Yoo, Professor — Samsung Medical Center
- Study coordinator: Hee Young Ju
- Email: hyju320@gmail.com
- Phone: 82-02-3410-0865
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.